Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 3,875 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: fast Clear all
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
347
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 13, 2026, 1:13 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Can Intermittent Fasting Mimic the Metabolic and Cardiovascular and Anti-aging Effects of Calorie Restriction?

NCT01964118
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Intermittent Fasting group, control group
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Nov 13, 2026, 1:13 PM EST
Completed Phase 3 Interventional Results available

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

NCT02273180
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, Humalog, Insulin glargine HOE901
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
47
States / cities
Tucson, Arizona • Bell Gardens, California • Chula Vista, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Nov 13, 2026, 1:13 PM EST
Approved For Marketing No phase listed Expanded access

Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma

NCT04534322
View directory record Official record
Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
Melphalan Flufenamide, Dexamethasone
Drug
Lead sponsor
Oncopeptides AB
Industry
Eligibility
18 Years and older
U.S. locations
11
States / cities
Springdale, Arkansas • Coeur d'Alene, Idaho • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Nov 13, 2026, 1:13 PM EST
Completed No phase listed Observational Results available

Cognition and Smoking Relapse (HCS)

NCT03169101
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine patch, Behavioral counseling
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Nov 13, 2026, 1:13 PM EST
Not listed No phase listed Observational

Utility of Rapid Whole Genome Sequencing in the NICU: A Pilot Study

NCT03918707
View directory record Official record
Conditions
Genetic Disease, Genetic Syndrome
Interventions
Rapid Whole Genome Sequencing (rWGS)
Diagnostic Test
Lead sponsor
University of Illinois College of Medicine at Peoria
Other
Eligibility
0 Months to 4 Months
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Nov 13, 2026, 1:13 PM EST
Completed Not applicable Interventional

Can we Safely Have Our Patients Eat With Cardiac Catheterization - Nix Or alloW: The CHOW NOW Study

NCT02373527
View directory record Official record
Conditions
Chest Pain
Interventions
No Fasting prior to catheterization
Other
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Sayre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Nov 13, 2026, 1:13 PM EST
Completed Not applicable Interventional Results available

An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy

NCT05709860
View directory record Official record
Conditions
HIV Infections, Electronic Health Record, Primary Health Care
Interventions
EMC2 PrEP Educational Tool, Discrete Scheduling of a Dedicated PrEP Visit
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Nov 13, 2026, 1:13 PM EST
Completed Phase 1 Interventional

Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery

NCT00488423
View directory record Official record
Conditions
Diabetes, Gastric Bypass
Interventions
Mixed Meal Tolerance test, Hyperglycemic clamp
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
19 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Nov 13, 2026, 1:13 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg

NCT00649688
View directory record Official record
Conditions
Healthy
Interventions
Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg, Lopressor HCT® Tablets 100/50 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Nov 13, 2026, 1:13 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

NCT02654002
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Nov 13, 2026, 1:13 PM EST
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

NCT05715281
View directory record Official record
Conditions
Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Tiragolumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 13, 2026, 1:13 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer

NCT04763902
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Time Restricted Eating (TRE) Schedule, Control Schedule
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 13, 2026, 1:13 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Adaptation and Implementation of Project Encuentro in the U.S.-Mexico Border

NCT03293875
View directory record Official record
Conditions
HIV
Interventions
Community Events, Social Network HIV Testing, Peer Network Intervention
Behavioral
Lead sponsor
City University of New York
Other
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Nov 13, 2026, 1:13 PM EST
Completed Not applicable Interventional Results available

Improvisational Movement for People With Memory Loss and Their Caregivers

NCT03333837
View directory record Official record
Conditions
Alzheimer's Disease (Incl Subtypes), Dementia, Mild Cognitive Impairment
Interventions
Dance Group, Non-Group Dance, Social Group, No Contact
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 85 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Nov 13, 2026, 1:13 PM EST
Completed Not applicable Interventional

Impact of Rapid Flu Testing in BMC ED

NCT02979730
View directory record Official record
Conditions
Influenza-Like Illness, Influenza
Interventions
Core Lab Test, ED Point of Care Test
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Nov 13, 2026, 1:13 PM EST
Completed Phase 1 Interventional

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

NCT00618735
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BIIB021
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Encinitas, California • Santa Monica, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Nov 13, 2026, 1:13 PM EST
Completed Phase 1 Interventional

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

NCT00083135
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, iobenguane I 131
Biological · Procedure · Radiation
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Nov 13, 2026, 1:13 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Rapid Effects of a Biofield Patch on Antioxidant Status and Cellular Energy

NCT07314359
View directory record Official record
Conditions
Antioxidant Status
Interventions
Active dermal patch, Placebo dermal patch
Other
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Nov 13, 2026, 1:13 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy

NCT01639443
View directory record Official record
Conditions
Colon Cancer
Interventions
Predictive no-show overbooking
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Nov 13, 2026, 1:13 PM EST
Not listed Phase 2 Interventional

Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

NCT01283789
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lapatinib and RAD-001
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Nov 13, 2026, 1:13 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

How Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses

NCT07121010
View directory record Official record
Conditions
Cardiometabolic Health
Interventions
Animal-Based Protein Smoothie, Plant-Based Protein Smoothie, Plant-Based Protein Smoothie with Leucine
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 13, 2026, 1:13 PM EST
Completed No phase listed Observational

Quick Start of Highly Effective Contraception

NCT02076217
View directory record Official record
Conditions
IUD, Contraceptive Implant, Contraception, Birth Control, Emergency Contraception
Interventions
Copper T-380 IUD, LNG IUD, Contraceptive implant Nexplanon, Depo-Provera
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 13, 2026, 1:13 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions

NCT01074450
View directory record Official record
Conditions
Healthy
Interventions
Pramipexole Dihydrochloride
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2010 · Synced Nov 13, 2026, 1:13 PM EST